183 related articles for article (PubMed ID: 7913562)
1. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
Rakhmilevich AL
Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
[TBL] [Abstract][Full Text] [Related]
2. Mobilization of T lymphocytes following cardiac transplantation. Evidence that CD4-positive cells are required for cytotoxic T lymphocyte activation, inflammatory endothelial development, graft infiltration, and acute allograft rejection.
Bishop DK; Shelby J; Eichwald EJ
Transplantation; 1992 Apr; 53(4):849-57. PubMed ID: 1533070
[TBL] [Abstract][Full Text] [Related]
3. [Combination of CD4+ CD25+ regulatory T cell and costimulatory pathway blockade inhibits acute rejection after liver transplantation: experiment with rats].
Shi LB; Zhang HW; Peng CH
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(14):942-6. PubMed ID: 17650415
[TBL] [Abstract][Full Text] [Related]
4. Roles of CD4+ and CD8+ cells in islet allo- and xeno-graft rejection.
Gotoh M; Monden M; Yamamoto H; Kawai M; Ichikawa T; Mori T; Uenaka A; Nakayama E
Horm Metab Res Suppl; 1990; 25():173-6. PubMed ID: 1982441
[TBL] [Abstract][Full Text] [Related]
5. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
[TBL] [Abstract][Full Text] [Related]
6. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
[TBL] [Abstract][Full Text] [Related]
7. Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation.
Shepherd DM; Kerkvliet NI
J Immunol; 1999 Sep; 163(5):2470-7. PubMed ID: 10452982
[TBL] [Abstract][Full Text] [Related]
8. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
Xia G; He J; Zhang Z; Leventhal JR
Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
[TBL] [Abstract][Full Text] [Related]
9. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
Ellenhorn JD; Schreiber H; Bluestone JA
J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
[TBL] [Abstract][Full Text] [Related]
11. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
[TBL] [Abstract][Full Text] [Related]
12. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
Lamousé-Smith E; Clements VK; Ostrand-Rosenberg S
J Immunol; 1993 Dec; 151(11):6283-90. PubMed ID: 8245467
[TBL] [Abstract][Full Text] [Related]
13. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
14. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
15. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD40L monoclonal antibodies can replace anti-CD4 monoclonal antibodies for the nonmyeloablative induction of mixed xenogeneic chimerism.
Ito H; Takeuchi Y; Shaffer J; Sykes M
Transplantation; 2006 Jul; 82(2):251-7. PubMed ID: 16858289
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
[TBL] [Abstract][Full Text] [Related]
18. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Buhlman J; Xu J; Flavell RA; Korngold R; Noelle R; Vallera DA
J Immunol; 1997 Jan; 158(1):29-39. PubMed ID: 8977172
[TBL] [Abstract][Full Text] [Related]
20. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor.
Fioretti F; Fradelizi D; Stoppacciaro A; Ramponi S; Ruco L; Minty A; Sozzani S; Garlanda C; Vecchi A; Mantovani A
J Immunol; 1998 Jul; 161(1):342-6. PubMed ID: 9647242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
